REGIMEN DE DOSIS BAJA Y FORMULACION DE UN COMPUESTO 5-METIL-1,2,4-OXADIAZOL-3-ILO

• Main Authors: KIELBASA, William Brian, MERGOTT, Dustin James
• Format: Patent
• Language: Spanish
• Published: 10.07.2023
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Esta referido a un regimen de dosis baja y una formulacion de dosis baja del inhibidor de O-GlcNAcase (OGA) N-[4-fluoro-5-[[(2S,4S)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1- piperidil]metil]tiazol-2-il]acetamida, o una sal farmaceuticamente aceptable de esta, para tratar enfermedades neurodengerativas, incluidas tauopatias neurodegenerativas como la enfermedad de Alzheimer (AD), demencia frontotemporal (FTD), sindrome corticobasilar (CBS) y paralisis supranuclear progresiva (PSP). Este compuesto se administra por via oral con una dosis total del compuesto de 0,1 mg/dia a 5 mg/dia The present invention provides a compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegenerative disease, including neurodegenerative tauopathies, such as Alzheimer's disease, frontotemporal dementia, corticobasilar syndrome, and progressive supranuclear palsy.